As indicated by existing studies, SYCP2 belonging to the mitosis pathway is likely to play a certain role in the oncogenesis of cervical carcinoma and can be used as a diagnostic marker and therapeutic target (Espinosa et al., 2013); SYCP2 with alternative spliced events is likely to facilitate the CSCC progression (Guo et al., 2015). The gene discussed is SYCP2; the disease is cervical carcinoma.